JPH0319388Y2 - - Google Patents
Info
- Publication number
- JPH0319388Y2 JPH0319388Y2 JP16338685U JP16338685U JPH0319388Y2 JP H0319388 Y2 JPH0319388 Y2 JP H0319388Y2 JP 16338685 U JP16338685 U JP 16338685U JP 16338685 U JP16338685 U JP 16338685U JP H0319388 Y2 JPH0319388 Y2 JP H0319388Y2
- Authority
- JP
- Japan
- Prior art keywords
- cervix
- laminaria
- drug administration
- tube
- rod
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 210000003679 cervix uteri Anatomy 0.000 claims description 25
- 238000001647 drug administration Methods 0.000 claims description 18
- 210000004291 uterus Anatomy 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 8
- 230000035935 pregnancy Effects 0.000 claims description 4
- 230000006698 induction Effects 0.000 claims description 2
- 230000000916 dilatatory effect Effects 0.000 claims 1
- 241001466453 Laminaria Species 0.000 description 20
- 238000010586 diagram Methods 0.000 description 7
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 210000001215 vagina Anatomy 0.000 description 4
- 206010000210 abortion Diseases 0.000 description 3
- 231100000176 abortion Toxicity 0.000 description 3
- 230000008602 contraction Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
Landscapes
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Description
【考案の詳細な説明】
［考案の技術分野］
本考案は、子宮内薬剤投与チユーブ、特に妊娠
中絶時等に子宮口に挿入して使用する子宮内薬剤
投与チユーブに関するものである。[Detailed Description of the Invention] [Technical Field of the Invention] The present invention relates to an intrauterine drug administration tube, particularly an intrauterine drug administration tube that is inserted into the cervix and used during abortion or the like.
［考案の技術的背景］
一般に、妊娠中では子宮口ががつちりと閉じて
いるのが普通である。しかし、妊娠中絶時、特に
妊娠中期における中絶時及び分娩誘発をする時に
は、子宮口を開かせる必要がある。第３図ないし
第６図を用いて従来方式を説明する。[Technical background of the invention] Generally, during pregnancy, the cervix normally closes tightly. However, it is necessary to open the cervix during abortion, especially during the second trimester, and when inducing labor. The conventional method will be explained using FIGS. 3 to 6.
先ず、第３図は妊娠中の子宮の正常状態図であ
り、子宮１内には胎児２があり、子宮口（頸管）
３はがつちりと閉じていて、その先端はやゝ腟内
４に突出した状態となつている。 First, Figure 3 shows the normal state of the uterus during pregnancy. There is a fetus 2 inside the uterus 1, and the cervix (cervix)
3 is tightly closed, and its tip is now protruding into the vagina 4.
この状態において、中絶時の場合には、子宮口
３を開かせなければならず、一般には第４図に示
すラミナリア桿５が使用される。 In this state, in case of abortion, the cervix 3 must be opened, and generally a laminaria rod 5 shown in FIG. 4 is used.
即ち、ラミナリア桿５とは、第４図ａに示され
るように海草の茎で使られた細い棒状の形をして
おり、これが水分を吸収した際、第４図ｂに示さ
れるように数倍の太さに膨脹するものである。 That is, the laminaria rod 5 has the shape of a thin rod used in seaweed stems as shown in FIG. It expands to twice its thickness.
従つて、第５図に示されるように、先ず、乾燥
状態にあるラミナリア桿５を子宮口３に数本挿入
し、約24時間放置すると、このラミナリア桿５が
膨脹して５′のようになり、第６図の如く、子宮
口３を大きく開く。 Therefore, as shown in FIG. 5, first, several dry laminaria rods 5 are inserted into the cervix 3 and left for about 24 hours, then the laminaria rods 5 expand and become like 5'. Then, as shown in Figure 6, the cervix 3 is opened wide.
このようにして、通常は子宮口を充分拡大させ
た上で、更に陣痛促進剤を注射又は内服により与
えて、流産又は分娩に至らせている。 In this way, the cervix is usually sufficiently dilated and then a labor stimulant is given by injection or internally to induce miscarriage or delivery.
［背景技術の問題点］
上記した従来方式では、ラミナリア桿を挿入し
て子宮口を拡大した状態で陣痛促進剤を投与する
ものである。この場合、子宮内への陣痛促進剤の
投与もあるが、ラミナリア桿の挿入後の投与は極
めて困難である。[Problems with Background Art] In the conventional method described above, a labor stimulant is administered with the cervix expanded by inserting a laminaria rod. In this case, a labor stimulant may be administered into the uterus, but administration after insertion of the laminaria rod is extremely difficult.
又、子宮内への陣痛促進剤の投与は、一旦、投
与すると投与量をコントロールすることが出来な
いため、その与えた量が過少投与であつたり、過
量投与であつたりする。又、過量投与の場合は、
過強陣痛となつて子宮破裂を起こしかねない。 Furthermore, once a labor stimulant is administered into the uterus, the dose cannot be controlled, so the amount administered may be an underdosage or an overdosage. Also, in case of overdose,
The contractions may become so strong that the uterus may rupture.
従つて、ラミナリア桿挿入後において、子宮の
収縮状態を監視しながら順次子宮内への薬剤を投
与できる手段の出現が望まれている。 Therefore, there is a desire for a means to sequentially administer drugs into the uterus while monitoring the state of contraction of the uterus after insertion of the laminaria rod.
［考案の目的］
本考案は、上記問題点を解決するためになされ
たものであり、ラミナリア桿を挿入した状態にお
いて子宮内への薬剤の投与の可能な子宮内薬剤投
与チユーブを提供することを目的としている。[Purpose of the invention] The present invention was made to solve the above problems, and aims to provide an intrauterine drug administration tube that can administer drugs into the uterus with a laminaria rod inserted. The purpose is
［考案の概要］
本考案では、鍔と一体になつた外筒の管状部に
対して同じく鍔と一体になつた内筒を挿通自在と
し、この鍔部を四角の翼状とすると共に、この翼
状の長手方向の各対応位置に溝を設けて把持し易
くしたものである。[Summary of the invention] In this invention, the inner cylinder, which is also integrated with the flange, can be freely inserted into the tubular part of the outer cylinder, which is integrated with the flange, and the flange is shaped like a square wing. Grooves are provided at corresponding positions in the longitudinal direction to make it easier to grip.
［考案の実施例］ 以下図面を参照して実施例を説明する。[Example of idea] Examples will be described below with reference to the drawings.
第１図は、本考案による子宮内薬剤投与チユー
ブの一実施例の構成図であり、第１図ａは全体斜
視図、第１図ｂは、第１図ａのＸ−X′線から見
た縦断断面図、第１図ｃは、第１図ｂの矢印方向
から見た図である。 FIG. 1 is a configuration diagram of an embodiment of an intrauterine drug administration tube according to the present invention, FIG. 1a is an overall perspective view, and FIG. 1b is a view taken from the line The vertical sectional view, FIG. 1c, is a view seen from the direction of the arrow in FIG. 1b.
第１図において、６は子宮内薬剤投与チユーブ
本体であり、外筒７の管状部には内筒８が挿通可
能となつており、更に外筒７の一方端には鍔９が
一体に形成されている。又、内筒８の端部には、
同じく鍔１０が設けられる。これらの各鍔９，１
０の形状は四角形の翼状を有し、これら各翼状を
有する長手方向端には、夫々対応して溝１１，１
１及び１２，１２が設けてある。鍔の形状を翼状
にしたのは、子宮内薬剤投与チユーブ本体６を子
宮口に挿入した時、ラミナリア桿の挿入の邪魔に
ならないように考慮したものであると同時に、子
宮口へ挿入してからの操作性も考慮したものであ
る。 In FIG. 1, 6 is the main body of the intrauterine drug administration tube, and an inner tube 8 can be inserted into the tubular portion of the outer tube 7, and a collar 9 is integrally formed at one end of the outer tube 7. has been done. Moreover, at the end of the inner cylinder 8,
Similarly, a collar 10 is provided. Each of these tsuba 9,1
0 has a rectangular wing shape, and grooves 11 and 1 are provided at the longitudinal ends of each wing shape, respectively.
1 and 12, 12 are provided. The reason why the shape of the flange is winged is to prevent it from interfering with the insertion of the laminaria rod when the intrauterine drug administration tube body 6 is inserted into the cervix. This also takes into consideration the operability of the system.
即ち、子宮口は狭い腟の奥により、この子宮内
薬剤投与チユーブ本体６を子宮口３に挿入した
時、例えばゼゴン鉗子を腟内に挿入して、把持し
易くするためである。 That is, the cervix is narrow in the back of the vagina, so that when the intrauterine drug administration tube body 6 is inserted into the cervix 3, it is easy to insert and grasp Zegon forceps into the vagina.
次に、第２図を用いて使用方法を説明する。 Next, the method of use will be explained using FIG. 2.
先ず、子宮口３にラミナリア桿５を挿入する
時、前記した子宮内薬剤投与チユーブ本体６を、
ラミナリア桿の間に入れて一緒に挿入する。 First, when inserting the laminaria rod 5 into the cervix 3, the above-mentioned intrauterine drug administration tube body 6 is
Place it between the laminaria rods and insert them together.
これによつて、ラミナリア桿５により子宮口
（頸管）を拡大しつゝ、ラミナリア桿の挿入初期
より、この子宮内薬剤投与チユーブを介して子宮
内に陣痛促進剤の薬剤、例えばProstagrandin
E1、E22等を任意の時間に任意の回数で投与する
ことが出来る。 As a result, the cervix (cervix) is enlarged by the laminaria rod 5, and from the early stage of insertion of the laminaria rod, a labor-promoting drug, such as Prostagrandin, is injected into the uterus via this intrauterine drug administration tube.
E 1 , E 22 , etc. can be administered at any time and any number of times.
その際、薬剤は外筒７内に入れて内筒８を押圧
することにより、薬剤を子宮内に押し込む。そし
て、通常は外筒７内に内筒８を挿入したまゝにし
ておき、子宮内に投与した薬剤の流出を防止す
る。 At this time, the medicine is put into the outer cylinder 7 and the inner cylinder 8 is pressed, thereby pushing the medicine into the uterus. Normally, the inner tube 8 is left inserted into the outer tube 7 to prevent the drug administered into the uterus from flowing out.
なお、操作に際しては、外筒７と一体になつた
翼状の溝１１，１１をゼゴン鉗子によつて把持固
定し、この状態で管状部に薬剤を入れ、更に内筒
８の鍔部を把持して外筒７に押し込むようにす
る。なお、この場合の把持部位は、翼状の鍔に設
けた溝部分である。 In addition, during operation, the wing-shaped grooves 11, 11 that are integrated with the outer tube 7 are grasped and fixed with Zegon forceps, and in this state, the drug is introduced into the tubular part, and the flange of the inner tube 8 is further grasped. and push it into the outer cylinder 7. Note that the gripping portion in this case is a groove portion provided in the wing-shaped flange.
更に詳記すれば、子宮口に子宮内薬剤投与チユ
ーブを挿入し、このチユーブと子宮口との間隙に
ラミナリア桿を挿入充填する際、ラミナリア桿は
子宮内薬剤投与チユーブに沿つて挿入するため、
各鍔部の翼状部分の両側をカツトしているのであ
る。 More specifically, when inserting an intrauterine drug administration tube into the cervix and inserting and filling the gap between the tube and the cervix, the laminaria column is inserted along the intrauterine drug administration tube.
Both sides of the wing-shaped portion of each collar are cut.
このように、ラミナリア桿を子宮口（頸管）に
充填し、拡張している時に、上記実施例に示され
る子宮内薬剤投与チユーブを併用することによ
り、子宮内に薬剤を投与することが出来る。 In this way, when the laminaria rod is filled into the uterine os (cervix) and the cervix is being dilated, a drug can be administered into the uterus by using the intrauterine drug administration tube shown in the above embodiment.
［考案の効果］
以上説明した如く、本考案によれば外筒内に内
筒を挿通自在とし、この各内外筒の鍔部に四角の
翼状部を設けると共に、各翼状部の対向位置に溝
を設けて子宮内薬剤投与チユーブを形成したの
で、ラミナリア桿と共に子宮口（頸管）に挿入し
た場合に、子宮の収縮状態を見ながら、低容量か
ら逐次増量してゆく薬剤の投与が可能となり、従
つて妊娠（中期）中絶、又は分娩の誘発の所要時
間を短縮させることが可能であるばかりか、極め
て安全な操作の可能な子宮内薬剤投与チユーブを
提供することが出来る。[Effects of the invention] As explained above, according to the invention, the inner cylinder can be freely inserted into the outer cylinder, square wing-shaped parts are provided on the flanges of each of the inner and outer cylinders, and grooves are provided at opposing positions of each wing-shaped part. Since an intrauterine drug administration tube is formed by providing a tube, when inserted into the uterine os (cervical canal) together with a laminaria rod, it becomes possible to gradually increase the dose of the drug from a low dose while monitoring the state of uterine contractions. Therefore, it is possible not only to shorten the time required for (mid-term) pregnancy termination or induction of labor, but also to provide an intrauterine drug administration tube that can be operated extremely safely.
第１図は本考案による子宮内薬剤投与チユーブ
の一実施例の構成図、第２図は使用方法を説明す
る図、第３図は子宮の正常状態を説明する図、第
４図はラミナリア桿の説明図、第５図はラミナリ
ア桿の挿入初期を示す図、第６図はラミナリア桿
の膨脹により子宮口が拡大された状態図である。
１……子宮、２……胎児、３……子宮口（頸
管）、４……腟、５，５′……ラミナリア桿、６…
…子宮内薬剤投与チユーブ本体、７……外筒、８
……内筒、９，１０……鍔、１１，１２……溝。
Figure 1 is a configuration diagram of an embodiment of the intrauterine drug administration tube according to the present invention, Figure 2 is a diagram explaining how to use it, Figure 3 is a diagram explaining the normal state of the uterus, and Figure 4 is a diagram showing the laminaria rod. FIG. 5 is a diagram showing the initial stage of insertion of the laminaria rod, and FIG. 6 is a diagram showing the state in which the cervix is enlarged due to the expansion of the laminaria rod. 1... Uterus, 2... Fetus, 3... Cervix (cervix), 4... Vagina, 5,5'... Laminaria rod, 6 ...
... Intrauterine drug administration tube body, 7 ... Outer tube, 8
...Inner cylinder, 9, 10...Tsuba, 11,12...Groove.
Claims (1)
拡張しつゝ子宮内に薬剤を投与する子宮内薬剤投
与チユーブにおいて、鍔を有する外筒と、前記外
筒の管状部に挿通可能な鍔を有する内筒とを備
え、前記内外筒の各鍔は四角な翼状に形成すると
共に、前記翼状の長手方向端縁に夫々溝を形成し
たことを特徴とする子宮内薬剤投与チユーブ。 An intrauterine drug administration tube for dilating the cervix (cervix) and administering drugs into the uterus during pregnancy termination or induction of labor includes an outer cylinder having a flange and a flange that can be inserted into the tubular part of the outer cylinder. What is claimed is: 1. An intrauterine drug administration tube comprising: an inner tube having an inner tube, wherein each collar of the inner and outer tubes is formed into a square wing shape, and a groove is formed at a longitudinal end edge of the wing shape.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP16338685U JPH0319388Y2 (en) | 1985-10-24 | 1985-10-24 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP16338685U JPH0319388Y2 (en) | 1985-10-24 | 1985-10-24 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6272652U JPS6272652U (en) | 1987-05-09 |
| JPH0319388Y2 true JPH0319388Y2 (en) | 1991-04-24 |
Family
ID=31091534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP16338685U Expired JPH0319388Y2 (en) | 1985-10-24 | 1985-10-24 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH0319388Y2 (en) |
-
1985
- 1985-10-24 JP JP16338685U patent/JPH0319388Y2/ja not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6272652U (en) | 1987-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jones Jr et al. | On the transfer of conceptuses from oocytes fertilized in vitro | |
| Bugalho et al. | The effectiveness of intravaginal misoprostol (Cytotec) in inducing abortion after eleven weeks of pregnancy | |
| US3911911A (en) | Anti-fertility device | |
| EP0330786B1 (en) | Topical drug delivery systems containing danazol | |
| Diczfalusy et al. | OESTROGEN METABOLISM IN THE HUMAN FOETUS: II. Oestrogen conjugation by foetal organs in vitro and in vivo | |
| Mikhail et al. | Oestriol metabolism in the human foeto-placental unit | |
| JPH0319388Y2 (en) | ||
| Bygdeman et al. | Reassessment of systemic administration of prostaglandins for induction of midtrimester abortion | |
| Tang et al. | Medical abortion in the second trimester | |
| US5095010A (en) | Antigestagens, glucocorticoids and prostaglandins for induction of labor or for termination of pregnancy | |
| CN205612515U (en) | Be used for hemostatic device in uterus | |
| EP0501056A1 (en) | Danazol containing compositions for the treatment of endometriosis | |
| JPS60155118A (en) | Blended medicine for parturition inducement or pregnancy interruption | |
| US4004582A (en) | Intracervical contraceptive device | |
| Cheng et al. | Preoperative cervical dilatation with 15 (S) 15 methyl prosta-glandin E2 methyl ester in first trimester nulliparae—a double blind study | |
| Karim et al. | Intramuscular administration of 16 phenoxy ω 17, 18, 19, 20 tetranor PGE2 methyl sulfonylamide for pre-operative cervical dilatation in first trimester nulliparae | |
| DE2913036A1 (en) | Claw-type sterilisation pessary - is inserted solely from womb using hysteroscopy procedure | |
| Karim et al. | Prostaglandins: Pharmacology and clinical application | |
| Craft et al. | Intra-amniotic prostaglandin F2α and urea for abortion | |
| Toppozada et al. | Termination of pregnancy with fetal death in the second and third trimesters—the double balloon versus extra-amniotic prostaglandin | |
| Stubblefield | Current technology for abortion | |
| WO2019211832A1 (en) | Localized delivery of an active agent | |
| Leader et al. | Vaginally administered 16, 16-dimethyl-prostaglandin E2 as an agent for pre-operative cervical dilatation | |
| CN219814469U (en) | Three-dimensional intrauterine device | |
| Korda et al. | Termination of Pregnancy by Intra‐uterine Prostaglandin F2α |